Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections (Q38098807)

28 August 2017

Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections (English)

1 reference

28 August 2017

1 reference

hepatocellular carcinoma

1 reference

1 reference

1 reference

4

Gerardo Botti

1 reference

28 August 2017

Francesco Izzo

5

0 references

Luigi Buonaguro

object named as

Luigi Buonaguro

series ordinal

2

0 references

Maria Lina Tornesello

object named as

Maria Lina Tornesello

series ordinal

1

0 references

Franco M Buonaguro

series ordinal

6

object named as

Franco M Buonaguro

1 reference

28 August 2017

Fabiana Tatangelo

3

1 reference

28 August 2017

11 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

102

1 reference

28 August 2017

2

1 reference

28 August 2017

74-83

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Epidemiology of viral hepatitis and hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Living in the liver: hepatic infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Immunology of hepatitis B virus and hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatocellular carcinoma: molecular pathways and new therapeutic targets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Viral hepatocarcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Molecular pathogenesis of human hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Etiology-dependent molecular mechanisms in human hepatocarcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Identification of integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-producing human hepatocellular carcinoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Integration of hepatitis B virus DNA into the myeloid/lymphoid or mixed-lineage leukemia (MLL4) gene and rearrangements of MLL4 in human hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Molecular viral oncology of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Functional genomic studies: insights into the pathogenesis of liver cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Mutations in the p53 gene occur in diverse human tumour types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

P53 abnormalities and outcomes in colorectal cancer: a systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

7 January 2021

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Switching from life to death: the Miz-ing link between Myc and p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Integrating mutation data and structural analysis of the TP53 tumor-suppressor protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

How many mutant p53 molecules are needed to inactivate a tetramer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

7 January 2021

p53 mutations in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Carcinogens leave fingerprints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

TP53 mutations in human skin cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Time trends in Balkan endemic nephropathy incidence in the most affected region in Serbia, 1977-2009: the disease has not yet disappeared

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Mutational hot spot in the p53 gene in human hepatocellular carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

The aflatoxin-induced TP53 mutation at codon 249 (R249S): biomarker of exposure, early detection and target for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

p53 and regulation of DNA damage recognition during nucleotide excision repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Methylation, mutation and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

The contribution of endogenous sources of DNA damage to the multiple mutations in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Association between inducible nitric oxide synthase expression and p53 status in human esophageal squamous cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

p53: traffic cop at the crossroads of DNA repair and recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

An updated overview on Wnt signaling pathways: a prelude for more

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

beta-catenin destruction complex: insights and questions from a structural perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Wnt/beta-catenin signaling: components, mechanisms, and diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Wnt signaling in the intestinal epithelium: from endoderm to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

The many faces and functions of β-catenin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Wnt/beta-catenin signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Novel inhibitors of the PI3K family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatitis viruses, alcohol, and tobacco in the etiology of hepatocellular carcinoma in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Hepatocellular carcinoma in patients without cirrhosis in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Prevalence of alpha-papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

Structure and organization of the hepatitis C virus genome isolated from human carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGENO.2013.04.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGENO.2013.04.001

1 reference

28 August 2017

1 reference

PubMed ID

23583669